Distinguishing prostate-specific antigen bounces from biochemical failure after low-dose-rate prostate brachytherapy
| Autor: | Don Yee, John Amanie, Kevin Martell, John Pedersen, Nadeem Pervez, Cian Hackett, Sunita Ghosh, Albert Murtha, Ron S. Sloboda, Nawaid Usmani, Lanna Lan |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
relapse
medicine.medical_specialty Pathology Original Paper business.industry medicine.medical_treatment Biochemical failure Brachytherapy brachytherapy Urology prostatic neoplasms Surgery Prostate-specific antigen Oncology Cohort Medicine Doubling time prostate-specific antigen Radiology Nuclear Medicine and imaging Implant Low dose rate business Prostate brachytherapy |
| Zdroj: | Journal of Contemporary Brachytherapy |
| ISSN: | 2081-2841 1689-832X |
| Popis: | Purpose: The purpose of this study was to characterize benign prostate-specific antigen (PSA) bounces of at least 2.0 ng/mL and biochemical failure as defined by the Phoenix definition after prostate brachytherapy at our institution, and to investigate distinguishing features between three outcome groups: patients experiencing a benign PSA bounce, biochemical failure, or neither. Material and methods: Five hundred and thirty consecutive men treated with low-dose-rate brachytherapy with follow-up of at least 3 years were divided into outcome groups experiencing bounce, failure, or neither. A benign bounce was defined as a rise of at least 2.0 ng/mL over the pre-rise nadir followed by a decline to 0.5 ng/mL or below, without intervention. Patient and tumor characteristics, treatment variables, and PSA kinetics were analyzed between groups. Results: Thirty-two (6.0%) men experienced benign bounces and 47 (8.9%) men experienced failure. Men experiencing a bounce were younger (p = 0.01), had a higher 6-month PSA level (p = 0.03), and took longer to reach a final nadir (p < 0.01). Compared to the failure group, men with bounce had a lower pre-treatment PSA level (p = 0.01) and experienced a rise of at least 2.0 ng/mL that occurred sooner after the implant (p < 0.01) with a faster PSA doubling time (p = 0.01). Only time to PSA rise independently differentiated between bounce and failure (p < 0.01), with a benign bounce not being seen after 36 months post-treatment. Prostate-specific antigen levels during a bounce reached levels as high as 12.6 ng/mL in this cohort, and in some cases took over 5 years to decline to below 0.5 ng/mL. Conclusions: Although there is substantial overlap between the features of benign PSA bounces and failure, physicians may find it useful to evaluate the timing, absolute PSA level, initial response to treatment, and rate of rise when contemplating management for a PSA rise after low-dose-rate brachytherapy. J Contemp Brachytherapy 2014; 6, 3: 247–253 DOI: 10.5114/jcb.2014.45093 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|